biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
MRQ-27, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (272M-14)
vial of 0.5 mL concentrate (272M-15)
bottle of 1.0 mL predilute (272M-17)
vial of 1.0 mL concentrate (272M-16)
bottle of 7.0 mL predilute (272M-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
control
brain, endothelial cells
shipped in
wet ice
storage temp.
2-8°C
visualization
nuclear
Gene Information
human ... SMARCB1(6598)
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Analysis Note
 IVD |  IVD |  IVD |  RUO |
General description
INI-1, also known as SMARCB1, is one of the core subunit proteins of the ATP-dependent SWI/SNF chromatin remodeling complex. It is involved in chromatin remodeling and transcriptional regulation and functions as a tumor suppressor. Nuclear INI-1 expression is seen in virtually all normal human tissues and most malignancies but the INI-1 gene is often mutated or deleted in malignant rhabdoid tumors (MRT), including those arising in the central nervous system, leading to a lack of INI-1 expression.
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
INI-1 Positive Control Slides, Product No. 272S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
未找到合适的产品？
试试我们的产品选型工具.
法规信息
监管及禁止进口产品
此项目有
hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.
F Bourdeaut et al.
The Journal of pathology, 211(3), 323-330 (2006-12-08)
Rhabdoid tumours (RTs) are rare but highly aggressive tumours of childhood. Their rarity and their miscellaneous locations make the diagnosis particularly challenging for pathologists. Central nervous system and peripheral RTs have been associated with biallelic inactivation of the hSNF5/INI1/SMARCB1 (hSNF5/INI1)
Christine Haberler et al.
The American journal of surgical pathology, 30(11), 1462-1468 (2006-10-26)
Immunohistochemical lack of nuclear INI1 protein expression has been recently described as characteristic finding in atypical teratoid/rhabdoid tumors (AT/RTs), and has been suggested as useful marker to distinguish AT/RTs from other malignant pediatric central nervous system (CNS) tumors. In this
D J Fowler et al.
Fetal and pediatric pathology, 25(3), 159-168 (2006-10-25)
Primary extrarenal rhabdoid tumors (RT) are now recognized as a specific entity in pediatric oncological pathology practice. We present an unusual case of a small cell myxoid variant of a thoracic RT in an infant and highlight the importance of
Linlin Hao et al.
Oncology letters, 26(4), 428-428 (2023-09-04)
Multiple primary malignant neoplasms (MPMN) are defined as two or more primary malignancies diagnosed in an individual. There is no association between these cancers, which can be classified into synchronous and heterochronous cancers depending on the time of diagnosis. The
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持